anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a medical information processing device capable of providing medical information desired by a user without delay regardless of the location of the user.SOLUTION: A medical information processing device comprises a position information acquisition part, a meta information acquisition part, a parameter acquisition part, a candidate calculation part, a candidate output part and a movement control part. The position information acquisition part acquires position information of a user. The meta information acquisition part acquires meta information on medical information stored by a plurality of data centers by inspection units. The parameter acquisition part acquires information on a network environment of the plurality of data centers. The candidate calculation part calculates a candidate of the data center which is suitable for the user to use the medical information at the position represented by the position information on the basis of the meta information acquired with respect to inspection and the information on the network environment. The candidate output part presents the calculated candidate of the data center to the user. The movement control part moves the medical information to the data center designated by the user.SELECTED DRAWING: Figure 2
This study will enroll (implant) up to 202 hips in total according to the IFU and surgical technique. Of these, up to 135 will be revision hips and up to 67 will be primary hips. This is a dual cohort study (primary and revision); each subject will receive the G7 Acetabular System with the Freedom Constrained Vivacit-E bearing. To minimize potential bias and to maximize our ability to assess inter-site differences, each study site will target up to 27 primary hip arthroplasties and up to 54 revision hip arthroplasties (not exceed 81 implanted hips or 40% of total study population). Each site is encouraged to enroll (implant) both primary and revision subjects.
Prevention and treatment of intraepithelial neoplasia and benign pre-malignant conditions has become an important focus of the NCI's 2015 goal of eliminating suffering and death due to cancer, although very little is known about the factors that influence development of frank malignancy in those with high risk benign/precursor conditions. The Radiation Epidemiology and Biostatistics Branches of the NCI propose to evaluate the contribution of inherited genetic variation to benign pre-malignant breast conditions, and to subsequent breast cancer risk in women diagnosed with such conditions, in the Breast Cancer Serum Bank, a unique biospecimen resource housed at NCI since 1995. Premenopausal participants (N=2632) biopsied at an average age of 27 in 1977-1987, (many diagnosed with high risk benign breast conditions (moderate/florid breast hyperplasia and atypia)) were interviewed and provided a blood sample. Participant biopsy reports will be obtained for review and recoding, and participants will be traced for vital status and breast cancer development (expected n = 240 cases). Variants in genes related to hormone metabolism and cell signaling, processes implicated in the development of premalignant breast conditions, and in genes associated with cell cycle control and apoptosis, and thus possibly related to progression to breast cancer among women with premalignant breast conditions will be assessed at the NCI Central Genotyping Facility. We have a remarkable opportunity in this study to address scientific questions regarding breast carcinogenesis mechanisms at relatively little cost. Greater comprehension of the influence of inherited factors on distinct steps in the biological pathway, first from normal tissue to benign high risk breast tumors, and then hence the breast cancer, should contribute to our understanding of the molecular mechanisms that shape breast cancer development, and holds promise for the discovery and delivery of sound risk-adapted interventions for women with high risk premalignant conditions.
Patients will be enrolled in the study within 72 hours of stroke symptom onset. The protocol will be a 35-minute monitoring session, during which cerebral hemodynamics will be monitored with both DCS and TCD, while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide concentration, are continuously monitored. 5 minutes of baseline hemodynamics will be assessed, after which the subject will breath iNO for 5 minutes, followed by 5 minutes of room air. This iNO/room air cycle will be repeated with a total of 3 different iNO concentrations. The full protocol will require 35 minutes. Subjects will be undergo a final assessment at 24 hours after the monitoring session to determine any tolerability issues or adverse events.
Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Sorbitan- wool wax acid esters are used as emulsifying agents in the production of water-in-oil emulsions. The esters, esp. partial esters with a wool wax acid; sorbitol mole ratio of 1-2:1, give stable water-in-oil emulsions and are esp. useful in the prepn. of pharmaceutical agents such as salves, lotions and creams, cosmetics, etc. The esters can be made e.g. by esterification of wool wax acids with sorbitol at 230-250 degrees C, using an agent such as benzene, toluene, xylene, etc. as azeotroping agent for removal of the water formed and in the presence of 0.2% NaOMe to assist sorbitan formation, or by transesterifying wool wax methyl ester with sorbitan at 120-150 degrees C. The esters are used e.g. at 1-10 wt.%, esp. 2-8 wt.% on total emulsion, opt. together with other emulsifiers.
This is a randomized trial comparing the incidence of WON in patients with acute necrotizing pancreatitis, according to the placement or non-placement of an Advanix or a Cook Pancreatic Duct (PD) stent during Endoscopic Retrograde Cholangiopancreatography (ERCP) within 1-2 week of symptom onset. Patients will be randomly allocated to either treatment arm i.e. to either PD stent placement or no PD placement in a 1:1 ratio. The type of stent to be placed is at the discretion of the physician based on the clinical needs and presentation of the patient at the time of procedure. This is based on factors such as the size of the WON, the patient's anatomy, and other variables. Patients will be assessed at 4-6 weeks post-ERCP for the primary outcome measure, which is the incidence of WON on contrast-enhanced CT.
Cancer pain is the most feared symptom at end of life. Methadone has advantages over other opioids but is associated with significant variability in clinical response, making dosing challenging in practice. OPRM1 is the most studied pharmacogene associated with the pharmacodynamics of opioids, however reports on the association of the A118G polymorphism on opioid dose requirements are conflicting, with no reports including methadone as the primary intervention. This association study on OPRM1 A118G and response to methadone for pain management, includes a review of this genetic factor's role in inter-patient variability. Fifty-four adult patients with advanced cancer were recruited in a prospective, multi-centre, open label dose individualization study. Patient characteristics were not shown to influence methadone response, and no significant associations were observed for methadone dose or pain score. The findings of our review of association studies for OPRM1 A118G in advanced cancer pain demonstrate the importance of taking ancestry into account. While our sample size was small, our results were consistent with European populations, but in contrast to studies in Chinese patients, where carriers of the A118G polymorphism were associated with higher opioid dose requirements. Pharmacogenetic studies in palliative care are challenging, continued contribution will support future genotype-based drug dosing guidelines.
A method for the mobilization of a transposable element is provided. The method comprises the steps of a) providing an inhibitor of DNA methylation, and/or an inhibitor of transcription, and b) contacting the inhibitor(s) with a cell comprising inactivated transposable elements, yielding a cell with mobilized transposable elements. In a second aspect of the invention a method for increasing the genetic and/or epigenetic variation in a plurality of eukaryotic organisms is provided. The method comprises the steps of i. providing an inhibitor of DNA methylation and/or an inhibitor of transcription, ii. contacting the organism with the inhibitor(s) and iii. propagating the organism.
As with any injected product, acute hypersensitivity or allergic reactions are possible. Limited reports have been received of hypersensitivity reactions following administration of Tc99m labeled leukocytes prepared using Tc99m exametazime. However, the materials used in leukocyte cell separation may cause hypersensitivity reactions. It is essential that cells are washed free of sedimentation agents before they are reinjected into the patient.

In case of side effects following administration of radiopharmaceuticals, users should ensure the availability of appropriate medical treatment at the time of administration of any radiopharmaceutical to the patient.

A thorough knowledge of the normal distribution of intravenously administered technetium Tc99m exametazime injection is essential in order to interpret pathologic studies accurately. Caution should be exercised in making the final diagnosis. Results can be affected by the presence of tumor, infarction, peritonitis, non-gastrointestinal or bony sites of inflammatory cell collections.

The contents of the Ceretec vial are not radioactive. After the sodium pertechnetate Tc99m is added, the product is radioactive and adequate shielding of the final preparation must be maintained. The contents of the Ceretec vial are intended only for use in preparation of technetium Tc99m exametazime injection and are NOT to be administered directly to the patient.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a medicinal agent comprising an active substance and special additions. As an active substance the agent comprises N-(6-methyl-2,4-dioxo-1,2,3-tetrahydro-5-pyrimidinsulfon)-N'-iso- nicotinoylhydrazide or its pharmaceutically acceptable salts and isomers taken in the effective dose. Except for, the proposed medicinal agent can comprise additionally at least one an antituberculosis agent, such as isoniazid, rifampicin, pyrazinamide. Proposed medicinal agent can be made as tablets, combined tablets, capsules, syrup and injections. Medicinal agent shows the reduced toxicity and improved stability in storage. EFFECT: improved properties of agent. 4 cl, 23 tbl, 6 ex
The introductory characteristics form consists of four closed-ended questions (age, gender, GPA, graduated high school) prepared to determine the demographic characteristics of the students. The movement requirement knowledge test consists of 15 questions, each of which has five options, prepared by the researchers in line with the literature in order to determine the students' knowledge levels about their movement needs. The questions were prepared in accordance with Bloom's taxonomy. In this context, considering that the students are in the first grade, three questions are for knowledge, three for comprehension, three for analysis, three for synthesis, and three for evaluation. After the test is prepared, it will be examined by a total of three experts, including a faculty member who is an expert in the field of Measurement and Evaluation and two faculty members who are experts in the field of Nursing Principles (1: Appropriate, 2: Appropriate but insufficient, 3: Not suitable). The concordance between expert opinions will be analyzed by Kendall's W test. Correct answers in the test will be evaluated as "10" points and wrong answers as "0" points. In this context, a minimum of "0" points and the highest "150" points can be obtained from the test. An increase in the score obtained from the test will show that the students' level of knowledge about movement needs is high. In the case analysis, correct answers given by the students will be evaluated as "10" points, and incorrect answers as "0" points. In this context, points will be made according to each correct and incorrect answer given by the students to the open-ended questions. An increase in the score will show that the students' case analysis skills for movement needs are high. The student opinion evaluation form on interactive learning was prepared by the researchers by scanning the literature in order to evaluate the opinions of the students in the experimental group about the interactive learning method. In this context, the form consists of 10 questions including five-point Likert-type scoring. After the theoretical training, the principal researcher will give the students an introductory feature form and will be asked to fill it in the classroom.Movement requirement knowledge test and evaluation case pre-test and post-test applications will be made. At the end of the study, students in the experimental group will be asked to fill in an evaluation form for the interactive learning method in order to get their opinions on the interactive learning method.
Following the baseline assessment, participants will be randomly assigned to one of the study groups. A popular and commonly used sound therapy treatment, this treatment group will listen to a broadband noise, or "white noise," that is housed on the manufacturer's hearing aid tinnitus program. They will be seen at a baseline, 4 week, and 8 week visits for outcome measures and any adjustments in hearing aid comfort.
FIELD: medicine. SUBSTANCE: invention relates to acylated derivatives of enzymes - 4-(N,N,N-trimethylamino)-cinnamoyl derivatives of fibrinolytic enzymes: urokinase, plasminogen and plasmin tissue activators, activating complexes of plasmin-and plasminogen-streptokinase. Method of preparing these acylated derivatives of enzymes involves acylation of fibrinolytic enzymes by serine residue in an active center with an excess of 4-(N,N,N-trimethylamino)-cinnamic acid 4-nitrophenyl ester. Acylation is carried out at 0-25 C and pH 7.0-8.5 for 10-70 min in the absence of an organic solvent. The obtained acylenzymes are separated from unreacted acylating agent and the formed 4-nitrophenyl ester by gel-filtration or ultrafiltration and protein fractions are lyophilized. The prepared agents can be used for treatment of patients with thromboembolic diseases. EFFECT: improved method of preparing. 2 cl, 1 tbl, 7 ex
PURPOSE:To provide the titled promoting agent containing the extract of YOKUININ (speed of adlay) having a specific molecular weight as an active component. CONSTITUTION:Raw or dried YOKUININ is extracted with an alcohol solution having a concentration of >=50wt%, and if necessary, the extract is filtered, and then concentrated by removing the solvent. For the effective extraction of the active component, it is preferable to use ethanol of 50-80% concentration. The extraction is preferably carried out at 40-70 deg.C for several hours - several days. The F-2 fraction obtained by this process is soluble easily in hydrophilic organic solvent, and the objective sebum-secretion promoting agent can be prepared in the form of a peroral drug, drink, transcutaneous drug, etc. by diluting or dissolving the fraction in water or alcohol, etc. Dose: 1-500mg, preferably 10-100mg of the dried F-2 fraction per kg daily. YOKUININ is a traditional crude drug for internal use and is effective to diuretic, antipyretic and anti- inflammatory purposes, etc.
Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. A method for making the microparticles is provided as well as methods for using the microparticles for controlled digestion of starch on ingestion in the small intestine and methods for using the microparticles to deliver dietary fiber. The microparticles with entrapped starch provide a low glycemic index and extended glucose release in food products and food ingredients. The microparticles with entrapped starch can, in particular, be used as an ingredient in foods that are to be cooked.
Retrograde intrarenal surgery (RIRS) is the recommended treatment for renal stones up to two cm in size. As digital health literacy (e-HL) has become increasingly important in promoting informed health decisions and healthy behaviors, it is necessary to investigate its impact on RIRS treatment outcomes. We aimed to explore the influence of patients' e-HL level on their postoperative quality of life (QoL). We conducted an observational prospective study of 111 patients who underwent RIRS for renal pelvis stones. Before RIRS, we evaluated patients' e-HL using the electronic health literacy scale (eHEALS). QoL was evaluated using the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) one month after RIRS. SFR was determined by a negative CT scan or asymptomatic patients with stone fragments < 3 mm. Adult individuals aged 18 years or older with typical calyceal anatomy met the eligibility criteria for enrollment. Exclusion criteria for the study included patients with ureteric stones, anomalous kidneys, or bilateral renal stones. The relationship between patients' QoL and stone-free rate was explored using Spearman's rank correlation coefficient. The mean stone burden was 14 ± 3 mm (6-19 mm). The overall SFR was 83.3% after one month. The median EQ-5D-5L utility index and VAS score were 0.826 (0.41-1) and 70 (20-100) respectively, for the overall population. We found that poorer e-HL was associated with being older (p = 0.035), having less education (p = 0.005), and not having access to the internet (p < 0.001). A significant difference was observed between patients with sufficient e-HL and patients with limited e-HL in the self-care (p = 0.02) and anxiety/depression (p = 0.021) dimensions. To date, no study has examined the impact of patients' e-HL levels on postoperative QoL in patients undergoing RIRS. This study also revealed that e-HL levels in patients undergoing RIRS were related to postoperative QoL, especially self-care and anxiety/depression dimensions, whereas there was no relationship between them and SFR.
Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic messenger RNA vaccine response in retrospective and prospective cohorts with lymphoma and chronic lymphocytic leukemia, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active treatment, but nonresponse was also common within observation and posttreatment groups. Total immunoglobulin A and immunoglobulin M correlated with successful vaccine response. In individuals treated with anti-CD19-directed chimeric antigen receptor-modified T cells, nonresponse was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to individualize vaccine timing.
PURPOSE: A massage pack and a massage pack kit containing the same are provided to perform paraffin therapy hygienically regardless of place. CONSTITUTION: A massage pack comprises a sponge and paraffin ingredient. The sponge has a form of mask for covering a face, glove for wearing hand, and socks for receipting feet. The sponge includes latex form, memory form, and melanin form. A massage pack kit comprises: a heating element which generates heat by chemical reaction with certain reaction solution; a first receptor for the heating element; a massage pack; and a second receptor for the massage pack. The heating element contains magnesium and iron.
This is a single-blind (where the participant does not know the treatment he receives), multicenter (study conducted at multiple sites), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), sequential design (it is a design in a single group of Participants where one or more study medication is administered in a sequence) study to evaluate the potential effects of a single-dose administration of trabectedin on the QT intervals of the electrocardiogram (ECG). Initially, the study will consist of 2 phases: a screening phase (within 21 days before administration of the study medication), and a single-blind treatment phase (for 2 days). Participants who complete the single-blind treatment phase will be opted to take trabectedin in an open-label extension (for a minimum of 6 cycles), as long as they derive a clinical benefit (ie, until there is clear evidence of disease progression or unacceptable toxicity, as judged by the investigator). Participants will be assessed for ECG on predose before the single-blind treatment phase. During the single-blind treatment phase, a placebo control will be given on Day 1, and trabectedin (1.3 mg per square meter) will be administered on Day 2. Participants will be monitored until completion of the 24 hour pharmacokinetic blood sample collection. During the open-label extension (21 days after completion of the single-blind treatment phase), all Participants will receive trabectedin intravenously on Day 1 of each 17- to 49 day treatment cycle. The dose and schedule of trabectedin will be modified according to the type of malignancy being treated (ie, sarcoma, ovarian, or breast cancer). Safety evaluations will include assessment of adverse events, vital signs, physical examination, and clinical laboratory tests which will be performed throughout the study. The study duration for the open-label extension will vary by participant.